GSK launches weight loss drug in Europe
GlaxoSmithKline (GSK) has received a non-prescription license for alli (orlistat 60mg); the first time the European Commission has approved a non-prescription product for weight loss. The centrally approved
Akeso has received approval from China’s National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to treat adults with moderate-to-severe plaque psoriasis.